It occured to me that a2 would be running down inventory of old stock prior to the change over to the new packaging and formulations. This may have delayed their approval by FDA, in that FDA would want to see the new formulations before they finalised approval. Frankly this is the most logical reason for the delay.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$8.09 |
Change
0.060(0.75%) |
Mkt cap ! $5.857B | |||
| Open | High | Low | Value | Volume |
| $8.05 | $8.11 | $8.02 | $12.16M | 1.507M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 985 | $8.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $8.10 | 1768 | 2 |
View Market Depth
| Last trade - 16.10pm 31/07/2025 (20 minute delay) ? |
| A2M (ASX) Chart |